These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Aberrant methylation of the CHFR gene in advanced hepatocellular carcinoma.
    Author: Sakai M, Hibi K, Kanazumi N, Nomoto S, Inoue S, Takeda S, Nakao A.
    Journal: Hepatogastroenterology; 2005; 52(66):1854-7. PubMed ID: 16334792.
    Abstract:
    BACKGROUND/AIMS: Recently, aberrant methylation of the CHFR gene associated with gene silencing has been reported in several cancers. We examined the methylation status of the CHFR gene in primary hepatocellular carcinomas (HCCs) and evaluated the correlation between the methylation status and the malignancy of HCC. METHODOLOGY: We first examined the methylation status of the CHFR promoter region and mRNA expression in cancer cell lines. Next, we examined the methylation status of the CHFR gene in 62 primary HCCs and then investigated the correlation between CHFR methylation and the clinicopathological findings. RESULTS: The cell line with CHFR promoter methylation showed a loss of CHFR expression that was restored after 5-aza-2'-deoxycytidine (5-aza-dC) treatment, suggesting that aberrant methylation of the CHFR gene was associated with gene silencing. CHFR methylation was detected in 22 of 62 (35%) primary HCCs, whereas no methylation was detected in noncancerous liver tissues. Furthermore, CHFR methylation was significantly associated with an infiltrative growth pattern (p=0.047) and an advanced stage (p=0.037). CONCLUSIONS: Aberrant methylation of the CHFR gene is significantly correlated with the progression of HCC, suggesting that CHFR methylation might be a novel molecular marker to estimate the malignancy of this disease.
    [Abstract] [Full Text] [Related] [New Search]